Longboard Pharmaceuticals, Inc. Common Stock
LBPH
LBPH was delisted on the 29th of November, 2024.
21 hedge funds and large institutions have $40.1M invested in Longboard Pharmaceuticals, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 1 closing their positions.
6% more capital invested
Capital invested by funds: $37.8M → $40.1M (+$2.32M)
0% more funds holding
Funds holding: 21 → 21 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$3.89M |
| 2 |
B
Bailard
Foster City,
California
|
+$101K |
| 3 |
IHAM
Integral Health Asset Management
New York
|
+$83.5K |
| 4 |
BlackRock
New York
|
+$59.6K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$8.74K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.43M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.21M |
| 3 |
Citigroup
New York
|
-$214K |
| 4 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$62.7K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$12.1K |
LBPH Hedge Fund Activity: Q1 2022 in Review
21 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Longboard Pharmaceuticals, Inc. Common Stock (LBPH) for Q1 2022, worth a combined $40.1M — up 6.1% from $37.8M a quarter earlier.
Fund positioning in LBPH was balanced in Q1 2022: 1 fund opened new positions, 1 closed out, 5 added to existing stakes and 5 trimmed.
The largest buyer was Millennium Management, adding an estimated $3.89M. The largest seller was T. Rowe Price Associates, cutting an estimated $2.43M.
- 21 institutional investors held Longboard Pharmaceuticals, Inc. Common Stock (LBPH) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $40.1M of Longboard Pharmaceuticals, Inc. Common Stock stock for Q1 2022, up 6.1% quarter-over-quarter.
- 1 fund opened new Longboard Pharmaceuticals, Inc. Common Stock positions in Q1 2022 and 1 closed out, a net change of 0 holders.
- The largest Longboard Pharmaceuticals, Inc. Common Stock buyer in Q1 2022 was Millennium Management, an estimated $3.89M added.
- The largest Longboard Pharmaceuticals, Inc. Common Stock seller in Q1 2022 was T. Rowe Price Associates, an estimated $2.43M sold.
Based on aggregated 13F filings for Q1 2022.